Pharmafile Logo
Pharmafocus logo
Advanced Search

Novartis

Showing 15 posts of 823 posts found.

Novartis’ Cosentyx has strong Phase 3 interim showing in axial spondyloarthritis

September 17, 2019
Manufacturing and Production, Research and Development Cosentyx, Novartis, pharma

Novartis has highlighted new data from its ongoing Phase 3 trial into the efficacy and safety of itsinterleukin-17A inhibitor Cosentyx …

News

Novartis announce robust Phase 3 trials for ofatumumab in MS

September 16, 2019
Research and Development, Sales and Marketing Aubagio, Novartis, multiple sclerosis

Novartis’ multiple sclerosis candidate has demonstrated strong results in its Phase 3 ASCLEPIOS trials meeting primary endpoints and slashing the …

News

Novartis’ Mayzent delays time wheelchair dependence by 4 years in secondary progressive multiple sclerosis

September 12, 2019
Research and Development ECTRIMS 2019, Mayzent, Novartis, multiple sclerosis, pharma

Novartis has taken the opportunity at the 2019 Congress of The European Committee for Treatment and Research in Multiple Sclerosis …

News
novartis_side_building

4.5-year data confirms long-term efficacy of Novartis’ Aimovig in episodic migraine

September 9, 2019
Research and Development, Sales and Marketing Aimovig, Novartis, migraine, pharma

Novartis has lifted the curtain on interim data from the 4.5-year mark of a five-year open-label treatment period (OLTP) investigating …

News
novartis_window

Novartis’ Lucentis secures European approval for infants with rare eye disease

September 6, 2019
Medical Communications, Sales and Marketing Europe, Lucentis, Novartis, eye disease, pharma

Novartis has made the surprise announcement that its VEGF inhibitor Lucentis (ranibizumab) has been awarded marketing authorisation from the European …

News

Experimental Novartis drug secures FDA Breathrough designation for rare lung cancer

September 6, 2019
Medical Communications, Sales and Marketing Cancer, Novartis, capmatinib, lung cancer, pharma

Novartis is celebrating the acceptance of its experimental cancer drug capmatinib by the FDA onto an accelerated review pathway, securing …

News
novartis_outside_1

Novartis’ ofatumumab outclasses Sanofi’s Aubagio at Phase 3 in relapsing multiple sclerosis

September 3, 2019
Manufacturing and Production, Research and Development Arzerra, Genmab, Novartis, multiple sclerosis, pharma

New data from two Phase 3 studies have indicated that Novartis’ ofatumumab outperformed Sanofi Genzyme’s Aubagio (teriflunomide) in the treatment …

News
novartis_outside_1

Novartis’ Entresto narrowly misses Phase 3 goal in heart failure patients

September 2, 2019
Research and Development, Sales and Marketing Entresto, Novartis, heart failure, pharma

New Phase 3 data for Novartis’ Entresto (sacubitril/valsartan) have been released, showing that the therapy narrowly missed its primary endpoint …

News
shutterstock_159488225

Genmab & Novartis’ ofatumumab tops Sanofi’s Aubagio in relapsing multiple sclerosis

August 30, 2019
Medical Communications, Research and Development Genmab, Novartis, multiple sclerosis, ofatumumab, pharma

Genmab and Novartis have revealed positive new data from two Phase 3 studies of its monthly subcutaneous formulation of ofatumumab …

News
linda_armstrong

Working Life: Linda Armstrong, Global Head, Respiratory Development Unit at Novartis

August 27, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, Working Life, feature, pharma

Linda Armstrong, Global Head, Respiratory Development Unit at Novartis.

Feature

Novartis exec pushed out over Zolgensma data scandal denies wrongdoing

August 21, 2019
Research and Development AveXis, FDA, Novartis, Zolgensma, data scandal, pharma, sma

Dr Brian Kaspar, the Novartis exec pushed out of AveXis over the Zolgensma data scandal, has said in a statement …

News
novartis_outside_1

Novartis exec sold off shares before Zolgensma data scandal was revealed

August 19, 2019
Sales and Marketing AveXis, Novartis, Shares, Zolgensma, pharma, stock market

An unnamed Novartis executive sold 925,400 Swiss francs (£778,665) worth of shares in the firm just weeks before the FDA …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

August 16, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Air pollution, CAR-T therapy, HIV, Kymriah, Medicare, Novartis, Yescarta, Zolgensma

Novartis’ faulty data scandal dominated the headlines this week, as the Swiss firm faced fierce backlash over covering up the …

News
25482028522_7a08ece5bb_z1

Senate Finance Comittee Chairman, Chuck Grassley calls on Novartis to reveal details of data scandal

August 13, 2019
Research and Development AveXis, Chuck Grassley, Novartis, Zolgensma, sfc

Chuck Grassley, Chairman of the Senate Finance Committee, has demanded that Novartis give up details on the faulty data scandal …

News

Senators call on FDA to use “forceful response” against Novartis over faulty data scandal

August 12, 2019
Sales and Marketing AveXis, Bernie Sanders, Elizabeth Warren, FDA, Novartis, Zolgensma

Five senators, including presidential candidates Bernie Sanders and Elizabeth Warren, have condemned Novartis for using “falsified data… to obtain approval …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025